A multicenter, Phase 3, randomized, open label, active-c

Project: Research project

Project Details

Description

A multicenter, Phase 3, randomized, open label, active-controlled, parallel-group trial investigating the safety, tolerability and efficacy of Transcon hGH administration once-a-week versus standard daily hGH replacement therapy over 52 weeks in pre-pube
StatusActive
Effective start/end date9/1/169/30/21

Funding

  • ASCENDIS PHARMA, INC.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.